Allied Market Research
Loading...
0
New
New
2021
Nasal Polyps Treatment Market

Nasal Polyps Treatment Market by Type of Treatment (Corticosteroids, Antibiotics, Leukotriene Inhibitors, and Others), Route of Administration (Oral, Nasal, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2030

A13674
Pages: NA
Sep 2021 | 214 Views
   
Author(s) : Linu Dash , Onkar Sumant
Tables: NA
Charts: 44
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Nasal Polyps Treatment Market

Request Now !

Nasal Polyps Treatment Market Overview:

The global nasal polyps treatment market size was valued at $2,482.7 million in 2020, and is projected to reach $4,243.9 million by 2030 registering a CAGR of 5.60% from 2021 to 2030. Nasal polyps are soft, painless, and noncancerous growths on lining of nasal passages or sinuses. It results from chronic inflammation and are associated with asthma, recurring infection, allergies, drug sensitivity, or certain immune disorders. Nasal polyp treatments such as medications are used to shrink or eliminate nasal polyps, as well as surgery is sometimes needed to remove them.

The COVID-19 pandemic has helped the industry grow significantly, as demand for antibiotics increased due to symptoms associated with nasal polyps such as loss in sense of smell and taste, feeling of congestion or stuffiness, and, in rare cases, difficulty breathing. This supports the nasal polyps treatment market to gain traction.

Increase in geriatric population suffering from chronic rhinosinusitis with nasal polyps (CRSwNP), rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and rich pipeline of nasal polyps treatment options with growing research activities are some factors that drive growth of the nasal polyps treatment market. However, high cost and complications associated with sinus surgeries such as excessive bleeding, cerebrospinal fluid leak, visual disturbances, postoperative scarring, and inflammation hamper growth of the market. In addition, adverse reactions associated with steroid therapies such as weight gain, loss of bone mineral density, and cataract formation in eyes restraint growth of the market. On the contrary, availability of key technologies such as nasal endoscopy and computerized tomography has created fresh opportunities for growth within the global nasal polyps treatment market.

Nasal-Polyps-Treatment-Market-2021-2030

Get more information on this report : Request Sample Pages

The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. However, there is positive impact of COVID-19 on the nasal polyps treatment market as demand for antibiotics increases due to symptoms associated with nasal polyps such as loss in sense of smell and taste, feeling of congestion or stuffiness, and, in rare cases, difficulty breathing. COVID-19 may affect upper or lower respiratory tract while in sinus infection, inflamed cavities around nasal passages can be observed. In addition, sinus infection and COVID-19 share similar symptoms, it is important to know the difference. As a result, in the ongoing pandemic, the nasal polyps treatment market is expected to grow, owing to increase in demand for diagnostic tests and antibiotics. Hence, the outbreak of COVID-19 has positively impacted the nasal polyps treatment market.

Nasal polyps treatment market segmentation 

The global nasal polyps treatment market is segmented on the basis of type of treatment, route of administration, distribution channel, and region to provide a detailed assessment of the market. By type of treatment, it is bifurcated into corticosteroids, antibiotics, leukotriene inhibitors, and others. Others include antihistamines. By route of administration, it is segmented into oral, nasal, and others. Others include injectable and topical. On the basis of distribution channel, it is categorized into hospitals pharmacies, retail pharmacies, and online pharmacies. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment Review

On the basis of type of treatment, the corticosteroids segment dominated the global market in 2020, and is expected to remain dominant throughout the forecast period, owing to factors such as increase in demand for corticosteroids treatment and its availability in various dosage forms such as injections, intranasal sprays, and drops according to the need of patients.

Nasal Polyps Treatment Market
By Type of Treatment

Your browser does not support the canvas element.

Corticosteroids segment holds a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

On the basis of route of administration, the nasal segment dominated the global market in 2020 and is anticipated to continue this trend during the forecast period. This is attributed to the fact that nasal delivery route is an encouraging way of delivering drugs into the body as compared to other drug delivery routes such as oral and others. This delivery route helps drugs to directly reach at the site of infection or allergic areas. Administration of drugs via nose provides a rapid action of drug in the body of patients.

Nasal Polyps Treatment Market
By Route of Administration

Your browser does not support the canvas element.

Nasal segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

On the basis distribution channel, the retail pharmacies segment held the largest market share in 2020, and is expected to remain dominant throughout the forecast period, owing to increase in preference by population, as it is the oldest and most conventional medium distributing nasal polyps treatment products such as corticosteroids, antibiotics, and leukotriene inhibitors to consumers, owing to its large chain of distribution network of pharmacies stores and availability of these products at retail stores at discounted price.

Snapshot of the Asia-Pacific Nasal Polyps Treatment Market

Asia-Pacific offers profitable opportunities for key players operating in the nasal polyps treatment market, which is expected to encourage fastest growth rate during the forecast period, owing to growth in healthcare infrastructure, increase in prevalence of nasal polyps and its associated disorders such as asthma, sinusitis, and rise in disposable incomes, well-established presence of domestic companies, and aging population in the region.

Nasal Polyps Treatment Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America is expected to experience growth at the highest rate, registering a CAGR of 4.90 % during the forecast period.

Get more information on this report : Request Sample Pages

The key nasal polyps treatment market players profiled in the report include AstraZeneca plc., F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Intersect ENT Inc., Merck & Co Inc., Novartis International AG, OptiNose US, Regeneron Pharmaceuticals Inc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global nasal polyps treatment market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the nasal polyps treatment market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing nasal polyps treatment market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of nasal polyps treatment used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the nasal polyps treatment market.

Key Market Segments

By Type of Treatment

  • Corticosteroids
  • Antibiotics
  • Leukotriene Inhibitors
  • Others 

By Route of Administration

  • Oral
  • Nasal
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA   
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population
3.5.1.2.Rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons
3.5.1.3.Huge product pipeline of nasal polyps treatment with growing research activities

3.5.2.Restraints

3.5.2.1.High cost and complications associated with sinus surgeries
3.5.2.2.Adverse reactions associated with steroid therapies

3.5.3.Opportunities

3.5.3.1.Technological improvement in nasal polyps treatment

3.5.4.Impact analysis

3.6.COVID-19 Impact analysis on the nasal polyps treatment market

CHAPTER 4:NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT

4.1.Overview

4.1.1.Market size and forecast

4.2.Corticosteroids

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Antibiotics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Leukotriene Inhibitors

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

4.5.Others

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast
4.5.3.Market analysis, by country

CHAPTER 5:NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Oral

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Nasal

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Others

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:NASAL POLYPS TREATMENT MARKET, DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospitals Pharmacies

6.2.1.Market size and forecast, by region
6.2.1.1.Market size and forecast for hospital pharmacies, by type of treatment
6.2.2.Market analysis, by country

6.3.Retail Pharmacies

6.3.1.Market size and forecast, by region
6.3.1.1.Market size and forecast for retail pharmacies, by type of treatment
6.3.2.Market analysis, by country

6.4.Online Pharmacies

6.4.1.Market size and forecast
6.4.1.1.Market size and forecast for online pharmacies, by type of treatment
6.4.2.Market analysis, by country

CHAPTER 7:NASAL POLYPS TREATMENT MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. nasal polyps treatment market, by type of treatment
7.2.2.1.2.U.S. nasal polyps treatment market, by route of administration
7.2.2.1.3.U.S. nasal polyps treatment market, by distribution channel

7.2.2.2.Canada

7.2.2.2.1.Canada nasal polyps treatment market, by type of treatment
7.2.2.2.2.Canada nasal polyps treatment market, by route of administration
7.2.2.2.3.Canada nasal polyps treatment market, by distribution channel

7.2.2.3.Mexico

7.2.2.3.1.Mexico nasal polyps treatment market, by type of treatment
7.2.2.3.2.Mexico nasal polyps treatment market, by route of administration
7.2.2.3.3.Mexico nasal polyps treatment market, by distribution channel

7.2.3.North America market size and forecast, by type of treatment
7.2.4.North America market size and forecast, by route of administration
7.2.5.North America market size and forecast, by distribution channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany nasal polyps treatment market, by type of treatment
7.3.2.1.2.Germany nasal polyps treatment market, by route of administration
7.3.2.1.3.Germany nasal polyps treatment market, by distribution channel

7.3.2.2.France

7.3.2.2.1.France nasal polyps treatment market, by type of treatment
7.3.2.2.2.France nasal polyps treatment market, by route of administration
7.3.2.2.3.France nasal polyps treatment market, by distribution channel

7.3.2.3.UK

7.3.2.3.1.UK nasal polyps treatment market, by type of treatment
7.3.2.3.2.UK nasal polyps treatment market, by route of administration
7.3.2.3.3.UK nasal polyps treatment market, by distribution channel

7.3.2.4.Italy

7.3.2.4.1.Italy nasal polyps treatment market, by type of treatment
7.3.2.4.2.Italy nasal polyps treatment market, by route of administration
7.3.2.4.3.Italy nasal polyps treatment market, by distribution channel

7.3.2.5.Spain

7.3.2.5.1.Spain nasal polyps treatment market, by type of treatment
7.3.2.5.2.Spain nasal polyps treatment market, by route of administration
7.3.2.5.3.Spain nasal polyps treatment market, by distribution channel

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe nasal polyps treatment market, by type of treatment
7.3.2.6.2.Rest of Europe nasal polyps treatment market, by route of administration
7.3.2.6.3.Rest of Europe nasal polyps treatment market, by distribution channel

7.3.3.Europe market size and forecast, by type of treatment
7.3.4.Europe market size and forecast, by route of administration
7.3.5.Europe market size and forecast, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan nasal polyps treatment market, by type of treatment
7.4.2.1.2.Japan nasal polyps treatment market, by route of administration
7.4.2.1.3.Japan nasal polyps treatment market, by distribution channel

7.4.2.2.China

7.4.2.2.1.China nasal polyps treatment market, by type of treatment
7.4.2.2.2.China nasal polyps treatment market, by route of administration
7.4.2.2.3.China nasal polyps treatment market, by distribution channel

7.4.2.3.Australia

7.4.2.3.1.Australia nasal polyps treatment market, by type of treatment
7.4.2.3.2.Australia nasal polyps treatment market, by route of administration
7.4.2.3.3.Australia nasal polyps treatment market, by distribution channel

7.4.2.4.India

7.4.2.4.1.India nasal polyps treatment market, by type of treatment
7.4.2.4.2.India nasal polyps treatment market, by route of administration
7.4.2.4.3.India nasal polyps treatment market, by distribution channel

7.4.2.5.South Korea

7.4.2.5.1.South Korea nasal polyps treatment market, by Type of treatment
7.4.2.5.2.South Korea nasal polyps treatment market, by route of administration
7.4.2.5.3.South Korea nasal polyps treatment market, by distribution channel

7.4.2.6.Rest of Asia-Pacific

7.4.2.6.1.Rest of Asia-Pacific nasal polyps treatment market, by type of treatment
7.4.2.6.2.Rest of Asia-Pacific nasal polyps treatment market, by route of administration
7.4.2.6.3.Rest of Asia-Pacific nasal polyps treatment market, by distribution channel

7.4.3.Asia-Pacific market size and forecast, by type of treatment
7.4.4.Asia-Pacific market size and forecast, by route of administration
7.4.5.Asia-Pacific market size and forecast, by distribution channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil nasal polyps treatment market, by type of treatment
7.5.2.1.2.Brazil nasal polyps treatment market, by route of administration
7.5.2.1.3.Brazil nasal polyps treatment market, by distribution channel

7.5.2.2.Saudi Arabia

7.5.2.2.1.Saudi Arabia nasal polyps treatment market, by type of treatment
7.5.2.2.2.Saudi Arabia nasal polyps treatment market, by route of administration
7.5.2.2.3.Saudi Arabia nasal polyps treatment market, by distribution channel

7.5.2.3.South Africa

7.5.2.3.1.South Africa nasal polyps treatment market, by type of treatment
7.5.2.3.2.South Africa nasal polyps treatment market, by route of administration
7.5.2.3.3.South Africa nasal polyps treatment market, by distribution channel

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA nasal polyps treatment market, by type of treatment
7.5.2.4.2.Rest of LAMEA nasal polyps treatment market, by route of administration
7.5.2.4.3.Rest of LAMEA nasal polyps treatment market, by distribution channel

7.5.3.LAMEA market size and forecast, by type of treatment
7.5.4.LAMEA market size and forecast, by route of administration
7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.ASTRAZENECA PLC

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance

8.2.F. Hoffmann-La Roche AG

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.GLAXOSMITHKLINE PLC

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.3.6.Key strategic moves and developments

8.4.Intersect ENT

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.MERCK & CO., INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.Novartis International AG

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.Optinose Inc.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.Regeneron Pharmaceuticals, Inc.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Sanofi S.A.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.TEVA PHARMACEUTICAL INDUSTRIES LIMITED

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

LIST OF TABLES

TABLE 01.GLOBAL NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 02.NASAL POLYPS TREATMENT MARKET FOR CORTICOSTEROIDS, BY REGION, 2020-2030($MILLION)
TABLE 03.NASAL POLYPS TREATMENT MARKET FOR ANTIBIOTICS, BY REGION, 2020-2030($MILLION)
TABLE 04.NASAL POLYPS TREATMENT MARKET FOR LEUKOTRIENE INHIBITORS, BY REGION, 2020-2030($MILLION)
TABLE 05.NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 06.GLOBAL NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 07.NASAL POLYPS TREATMENT MARKET FOR ORAL, BY REGION, 2020-2030($MILLION)
TABLE 08.NASAL POLYPS TREATMENT MARKET FOR NASAL, BY REGION, 2020-2030($MILLION)
TABLE 09.NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY REGION, 2020-2030($MILLION)
TABLE 10.GLOBAL NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 11.NASAL POLYPS TREATMENT MARKET FOR HOSPITALS PHARAMCIES, BY REGION, 2020-2030($MILLION)
TABLE 12.NASAL POLYPS TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 13.NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 14.NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 15.NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY REGION, 2020-2030($MILLION)
TABLE 16.NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 17.NASAL POLYPS TREATMENT MARKET, BY REGION, 2020-2030($MILLION)
TABLE 18.NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 19.U.S. NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 20.U.S. NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 21.U.S. NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 22.CANADA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 23.CANADA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 24.CANADA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 25.MEXICO NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 26.MEXICO NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 27.MEXICO NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 28.NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 29.NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 30.NORTH AMERICA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 31.EUROPE NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 32.GERMANY NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 33.GERMANY NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 34.GERMANY NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 35.FRANCE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 36.FRANCE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 37.FRANCE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 38.UK NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 39.UK NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 40.UK NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 41.ITALY NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 42.ITALY NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 43.ITALY NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 44.SPAIN NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 45.SPAIN NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 46.SPAIN NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 47.REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 48.REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 49.REST OF EUROPE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 50.EUROPE NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 51.EUROPE NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 52.EUROPE NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 53.ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 54.JAPAN NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 55.JAPAN NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 56.JAPAN NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 57.CHINA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 58.CHINA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 59.CHINA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 60.AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 61.AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 62.AUSTRALIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 63.INDIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 64.INDIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 65.INDIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 66.SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 67.SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 68.SOUTH KOREA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 69.REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 70.REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 71.REST OF ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 72.ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 73.ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 74.ASIA-PACIFIC NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 75.LAMEA NASAL POLYPS TREATMENT MARKET, BY COUNTRY, 2020-2030($MILLION)
TABLE 76.BRAZIL NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 77.BRAZIL NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 78.BRAZIL NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 79.SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 80.SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 81.SAUDI ARABIA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 82.SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 83.SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 84.SOUTH AFRICA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2030($MILLION)
TABLE 85.REST OF LAMEA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 86.REST OF LAMEA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 87.REST OF LAMEA NASAL POLYPS TREATMENT MARKET, DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 88.LAMEA NASAL POLYPS TREATMENT MARKET, BY TYPE OF TREATMENT, 2020-2030($MILLION)
TABLE 89.LAMEA NASAL POLYPS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030($MILLION)
TABLE 90.LAMEA NASAL POLYPS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2030($MILLION)
TABLE 91.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 92.ASTRAZENECA: OPERATING SEGMENTS
TABLE 93.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 94.ROCHE: COMPANY SNAPSHOT
TABLE 95.ROCHE: OPERATING SEGMENTS
TABLE 96.ROCHE: PRODUCT PORTFOLIO
TABLE 97.ROCHE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 98.GSK: COMPANY SNAPSHOT
TABLE 99.GSK: PRODUCT PORTFOLIO
TABLE 100.GSK: PRODUCT PORTFOLIO
TABLE 101.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.INTERSECTENT: COMPANY SNAPSHOT
TABLE 103.INTERSECTENT: OERATING SEGMENT
TABLE 104.INTERSECTENT: PRODUCT PORTFOLIO
TABLE 105.INTERSECTENT: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106.MERCK: COMPANY SNAPSHOT
TABLE 107.MERCK: OPERATING SEGMENTS
TABLE 108.MERCK: PRODUCT PORTFOLIO
TABLE 109.NOVARTIS: COMPANY SNAPSHOT
TABLE 110.NOVARTIS: OERATING SEGMENT
TABLE 111.NOVARTIS: PRODUCT PORTFOLIO
TABLE 112.NOVARTIS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 113.OPTINOSE: COMPANY SNAPSHOT
TABLE 114.OPTINOSE: OPERATING SEGMENTS
TABLE 115.OPTINOSE: PRODUCT PORTFOLIO
TABLE 116.OPTINOSE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117.REGENERON: COMPANY SNAPSHOT
TABLE 118.REGENERON: OERATING SEGMENT
TABLE 119.REGENERON: PRODUCT PORTFOLIO
TABLE 120.REGENERON: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 121.SANOFI: COMPANY SNAPSHOT
TABLE 122.SANOFI: OERATING SEGMENT
TABLE 123.SANOFI: PRODUCT PORTFOLIO
TABLE 124.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 125.TEVA: COMPANY SNAPSHOT
TABLE 126.TEVA: OERATING SEGMENT
TABLE 127.TEVA: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.NASAL POLYPS TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR ANTIBIOTICS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR LEUKOTRIENE INHIBITORS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS NASAL POLYPS TREATMENT MARKET FOR ORAL, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR NASAL, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR HOSPITALS PHARAMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 21.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 22.COMPARATIVE ANALYSIS OF NASAL POLYPS TREATMENT MARKET FOR ONLINE PHARMACIES, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 23.ASTRAZENECA: REVENUE, 2018–2020 ($MILLION)
FIGURE 24.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 25.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.GSK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.GSK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.INTERSECTENT: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 34.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 35.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.OPTINOSE: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.REGENERON: NET SALES, 2018–2020 ($MILLION)
FIGURE 40.SANOFI: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)

 
 

Nasal polyps is a non-cancerous growth that forms inside the nose. It is usually a painless condition. Large growths can lead to breathing problems and loss of sense of smell. Nasal polyp is mostly caused due to collection of fluids within the nose and continue to swell forming a polyp. Nasal polyps treatments include surgical treatment and non-surgical treatment such as oral, nasal corticosteroids, antibodies, and leukotriene inhibitors.

Increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population, rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and huge product pipeline of nasal polyps treatment with growing research activities are some factors that boost growth of the market. Furthermore, technological improvements in nasal polyps treatment is expected to create a lucrative opportunity for the market growth. However, high cost and complications associated with sinus surgeries and adverse reactions associated with steroid therapies are some factors expected to hinder growth of the market. 

The corticosteroids segment is expected to remain dominant during the forecast period, owing to increase in demand for corticosteroids treatment and its availability in various dosage forms such as injections, intranasal sprays, and drops according to the need of the patients. Moreover, North America are expected to offer lucrative opportunities to the market during the forecast period, owing to presence of major key players in the countries like the U.S. In addition, presence of a large population with nasal polyps, increase in incidences of CRSwNP, surge in number of sinus surgeries, and rapid adoption of technologically-advanced products such as sinus implants in the region.

 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of nasal polyps treatment market is $4,243.9 million in 2020.

A. The forcast period for nasal polyps treatment market is 2021 to 2030

A. The market value of nasal polyps treatment market in 2021 is $2,592.00 million.

A. The base year is 2020 in root canal sealer market

A. Top companies such as Sanofi S.A, GlaxosmithKline Plc., F. Hoffmann La Roche AG, Merck & Co. Inc., Teva Pharmaceuticals, Novartis International AG held a high market position in 2020.

A. corticosteroids segment is the most influencing segment owing to increase in the demand for corticosteroids treatment and its availability in various dosage forms like injections, intranasal sprays, and drops according to the need of the patient.

A. increase in prevalence of chronic rhinosinusitis with nasal polyps (CRSwNP) along with rise in geriatric population, rapid utilization of minimally-invasive surgeries by otorhinolaryngologist surgeons, and huge product pipeline of nasal polyps treatment with growing research activities are some factors which boost growth of the market. Furthermore, technological improvement in nasal polyps treatment expected to create a lucrative opportunity for market growth

A. Asia-Pacific is expected to experience the highest growth rate during the forecast period, owing to growing healthcare infrastructure, increasing prevalence of nasal polyps and its associated disorders such as asthma, sinusitis, rising disposable incomes, well-established presence of domestic companies, and aging population in the region.

A. Nasal polyps are a chronic inflammatory condition of the nose and paranasal sinuses

A. Nasal polyps treatment such as oral and nasal medications are used to shrink or eliminate nasal polyps.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Nasal Polyps Treatment Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers